Founder and CEO of VetStem Biopharma Joins Board of Directors for the American College of Regenerative Medicine
Founder and CEO of VetStem Biopharma, Dr. Bob Harman, was recently asked to join the board of directors for the American College of Regenerative Medicine.
Dr. Bob Harman, the founder and CEO of leading veterinary regenerative medicine company, VetStem Biopharma, was recently asked to join the Board of Directors for the American College of Regenerative Medicine (ACRM). Dr. Harman has nearly two decades’ worth of experience working with stem cells and regenerative medicine.
Dr. Harman co-founded VetStem Biopharma in 2002. As the first company in the United States to provide adipose-derived stem cell processing services to veterinarians and their patients, VetStem pioneered the use of regenerative stem cells in veterinary medicine. With over 15 years’ worth of veterinary clinical data, Dr. Harman spun off a human stem cell company, Personalized Stem Cells, Inc. (PSC) in 2018. PSC was launched to advance and legitimize stem cell therapy for humans through FDA approved clinical trials.
Dr. Harman has been a trailblazer in the field of regenerative medicine for nearly two decades and presents at both human and animal medical conferences around the world. He last spoke at Health Span Hawaii Summit to discuss the “data bridge” from veterinary regenerative medicine to human regenerative medicine. He applies his biotechnology and veterinary experience in the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. Dr. Harman has authored 17 peer-reviewed published papers and multiple book chapters.
Dr. Harman joins medical doctors and surgeons, a dentist, and a registered nurse on the ACRM Board of Directors. The diverse experience and collective knowledge of the Board of Directors is indicative of the interdisciplinary focus of the ACRM. Formed with a strong emphasis on global interdisciplinary collaboration, the ACRM aims to promote the science and ethical use of regenerative medicine in the United States and other affiliated countries. Dr. Harman stated, “I’m honored to join such an esteemed group of regenerative medicine advocates. I believe that an interdisciplinary focus on translational medicine, from animal to human and vice versa, will open the door for additional FDA approved regenerative therapies.”